Scholarlink

Introduction <p>Intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy is a standard treatment for neovascular age-related macular degeneration (nAMD) and diabetic macular oedema (DMO). A transient rise in intraocular pressure (IOP) following injection is a well-established short-term effect. Aflibercept 8&#xa0;mg has recently been introduced in a prefilled syringe (PFS), although data on its short-term effect on IOP are still lacking. The aim of this study was to assess short-term IOP changes after intravitreal aflibercept 8&#xa0;mg administered via PFS and to compare these results with historical cohorts receiving aflibercept 8&#xa0;mg via standard syringe and aflibercept 2&#xa0;mg via PFS.</p> Methods <p>This single-centre comparative observational cohort study included a prospectively enrolled cohort of patients with nAMD or DMO receiving aflibercept 8&#xa0;mg via PFS (0.07&#xa0;mL), while two retrospective historical cohorts receiving aflibercept 8&#xa0;mg via standard syringe (0.07&#xa0;mL) or aflibercept 2&#xa0;mg via PFS (0.05&#xa0;mL) were used for comparison. IOP was measured with the iCare IC200 rebound tonometer at baseline (T0), 30&#xa0;s (T1), 5&#xa0;min (T2), and 15&#xa0;min (T3) post-injection. Patients with glaucoma or ocular hypertension were excluded. Statistical analysis was performed using Friedman and Kruskal–Wallis tests.</p> Results <p>Forty-six eyes treated with aflibercept 8&#xa0;mg PFS were analysed. Baseline IOP was similar across the three groups (<i>p</i> = 0.54). In the aflibercept 8&#xa0;mg PFS cohort, mean IOP increased from 13.92 ± 4.25&#xa0;mmHg at baseline to 51.29 ± 15.07&#xa0;mmHg at 30&#xa0;s, then fell to 31.32 ± 12.24&#xa0;mmHg at 5&#xa0;min and to 20.25 ± 7.08&#xa0;mmHg at 15&#xa0;min (<i>p</i> &lt; 0.001). No statistically significant between-group differences were detected at any timepoint (all <i>p</i> ≥ 0.18).</p> Conclusion <p>Intravitreal aflibercept 8&#xa0;mg administered via PFS was associated with a transient rise in IOP immediately after injection, which resolved within 15&#xa0;min and was similar to that observed with aflibercept 2&#xa0;mg via PFS and aflibercept 8&#xa0;mg via standard syringe. These findings contribute to the characterization of the short-term IOP response associated with aflibercept 8&#xa0;mg PFS administration and may help inform routine clinical practice.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Short-Term Intraocular Pressure Changes After Intravitreal Aflibercept 8 mg via Prefilled Syringe

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月17日

查看全文
  • Arianna Peyla,
  • Matteo Bonanata,
  • Martina Pache,
  • Michele Clerici,
  • Moreno Menghini,
  • Gabriela Grimaldi,
  • Giulio Volpe

摘要

Introduction

Intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy is a standard treatment for neovascular age-related macular degeneration (nAMD) and diabetic macular oedema (DMO). A transient rise in intraocular pressure (IOP) following injection is a well-established short-term effect. Aflibercept 8 mg has recently been introduced in a prefilled syringe (PFS), although data on its short-term effect on IOP are still lacking. The aim of this study was to assess short-term IOP changes after intravitreal aflibercept 8 mg administered via PFS and to compare these results with historical cohorts receiving aflibercept 8 mg via standard syringe and aflibercept 2 mg via PFS.

Methods

This single-centre comparative observational cohort study included a prospectively enrolled cohort of patients with nAMD or DMO receiving aflibercept 8 mg via PFS (0.07 mL), while two retrospective historical cohorts receiving aflibercept 8 mg via standard syringe (0.07 mL) or aflibercept 2 mg via PFS (0.05 mL) were used for comparison. IOP was measured with the iCare IC200 rebound tonometer at baseline (T0), 30 s (T1), 5 min (T2), and 15 min (T3) post-injection. Patients with glaucoma or ocular hypertension were excluded. Statistical analysis was performed using Friedman and Kruskal–Wallis tests.

Results

Forty-six eyes treated with aflibercept 8 mg PFS were analysed. Baseline IOP was similar across the three groups (p = 0.54). In the aflibercept 8 mg PFS cohort, mean IOP increased from 13.92 ± 4.25 mmHg at baseline to 51.29 ± 15.07 mmHg at 30 s, then fell to 31.32 ± 12.24 mmHg at 5 min and to 20.25 ± 7.08 mmHg at 15 min (p < 0.001). No statistically significant between-group differences were detected at any timepoint (all p ≥ 0.18).

Conclusion

Intravitreal aflibercept 8 mg administered via PFS was associated with a transient rise in IOP immediately after injection, which resolved within 15 min and was similar to that observed with aflibercept 2 mg via PFS and aflibercept 8 mg via standard syringe. These findings contribute to the characterization of the short-term IOP response associated with aflibercept 8 mg PFS administration and may help inform routine clinical practice.